Cargando…

Differential response to biologics in a patient with severe asthma and ABPA: a role for dupilumab?

BACKGROUND: Allergic bronchopulmonary aspergillosis (ABPA) is a severe hypersensitivity reaction to aspergillus species colonizing the airways of patients with asthma or cystic fibrosis. Biologics including anti-IgE and anti-IL5 antibodies have strongly changed the treatment of severe asthmatics and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mümmler, Carlo, Kemmerich, Bernd, Behr, Jürgen, Kneidinger, Nikolaus, Milger, Katrin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491355/ https://www.ncbi.nlm.nih.gov/pubmed/32944023 http://dx.doi.org/10.1186/s13223-020-00454-w

Ejemplares similares

Real‐life effectiveness of biological therapies on symptoms in severe asthma with comorbid CRSwNP
por: Mümmler, Carlo, et al.
Publicado: (2021)

Reduced exacerbation frequency and prednisone dose in patients with ABPA and asthma treated with dupilumab
por: van der Veer, Tjeerd, et al.
Publicado: (2021)

Response to high-altitude triggers in seasonal asthmatics on and off inhaled corticosteroid treatment
por: Mertsch, Pontus, et al.
Publicado: (2022)

Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
por: Kayser, Moritz Z, et al.
Publicado: (2021)

Domestic Parasitic Infections in Patients with Asthma and Eosinophilia in Germany – Three Cases with Learnings in the Era of Anti- IL5 Treatments
por: Barnikel, Michaela, et al.
Publicado: (2023)

Bronchial asthma with ABPA presenting as PTE
por: Azad, Chandrika, et al.
Publicado: (2013)

Identification of a novel SERPINA-1 mutation causing alpha-1 antitrypsin deficiency in a patient with severe bronchiectasis and pulmonary embolism
por: Milger, Katrin, et al.
Publicado: (2015)

Pulmonary function impairment of asymptomatic and persistently symptomatic patients 4 months after COVID-19 according to disease severity
por: Munker, Dieter, et al.
Publicado: (2021)

Riociguat in Patients with CTEPH and Advanced Age and/or Comorbidities
por: Barnikel, Michaela, et al.
Publicado: (2022)

The Role of Dupilumab in Severe Asthma
por: Ricciardolo, Fabio Luigi Massimo, et al.
Publicado: (2021)

High prevalence of falsely declaring nicotine abstinence in lung transplant candidates
por: Veit, Tobias, et al.
Publicado: (2020)

A case report of ABPA, cystic fibrosis and asthma treated with omalizumab
por: Mazza, JA, et al.
Publicado: (2015)

Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma
por: Drick, Nora, et al.
Publicado: (2020)

Daily Chronic Intermittent Hypobaric Hypoxia Does Not Induce Chronic Increase in Pulmonary Arterial Pressure Assessed by Echocardiography
por: Götschke, Jeremias, et al.
Publicado: (2018)

Initiation, response assessment, and switch of antibody therapies in patients with severe asthma – A survey among German specialists
por: Suhling, Hendrik, et al.
Publicado: (2023)

Severe pediatric asthma therapy: Dupilumab
por: Ferrante, Giuliana, et al.
Publicado: (2022)

Review of current and future therapeutics in ABPA
por: Lewington-Gower, Elisa, et al.
Publicado: (2021)

Misdiagnosis of persistent asthma of a patient suffering from acute bronchopulmonary aspergillosis (ABPA)
por: Abuzneid, Yousef S., et al.
Publicado: (2021)

Clinical Impact of Physical Activity and Cough on Disease Progression in Fibrotic Interstitial Lung Disease
por: Veit, Tobias, et al.
Publicado: (2023)

Comprehensive transcriptome analysis of peripheral blood unravels key lncRNAs implicated in ABPA and asthma
por: Huang, Chen, et al.
Publicado: (2021)

Allergic Bronchopulmonary Aspergillosis (ABPA) Diagnosis Missed in the Context of Asthma Exacerbation Due to Medication Nonadherence
por: Rasheed, Waqas, et al.
Publicado: (2022)

Dupilumab and tezepelumab in severe refractory asthma: new opportunities
por: Ragnoli, Beatrice, et al.
Publicado: (2022)

Successful treatment with dupilumab for mucus plugs in severe asthma
por: Anai, Moriyasu, et al.
Publicado: (2022)

Basophil Activation Test With Aspergillus Molecules: The Case for ABPA
por: Michel, Moïse, et al.
Publicado: (2022)

An ALARMINg Type 2 Response in Cystic Fibrosis—The Key to Understanding ABPA?
por: Bojanowski, Christine M., et al.
Publicado: (2023)

Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13
por: Pelaia, Corrado, et al.
Publicado: (2022)

Dupilumab efficacy in adolescents with uncontrolled, moderate‐to‐severe asthma: LIBERTY ASTHMA QUEST
por: Maspero, Jorge F., et al.
Publicado: (2021)

Dupilumab in the management of moderate-to-severe asthma: the data so far
por: Barranco, Pilar, et al.
Publicado: (2017)

Dupilumab in the Treatment of Moderate to Severe Asthma: An Evidence-Based Review
por: Rathinam, Kiran Kumar, et al.
Publicado: (2019)

Asthma improvement in patients treated with dupilumab for severe atopic dermatitis
por: Dubini, Marco, et al.
Publicado: (2023)

Aspergillus march: from ABPA to aspergilloma to subacute invasive aspergillosis
por: Dogra, Vikas, et al.
Publicado: (2016)

Benralizumab as a First-line Treatment for ABPA: Is It Really Indicated?
por: Agarwal, Ritesh, et al.
Publicado: (2021)

Pulmonary actinomycosis and polymicrobial empyema in a patient with ABPA and bronchocoele
por: Tu, Jacky, et al.
Publicado: (2022)

Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma
por: Corren, Jonathan, et al.
Publicado: (2021)

Incidence, causes, and predictors of unsuccessful decannulation following prolonged weaning
por: Ghiani, Alessandro, et al.
Publicado: (2022)

Perception of climate change in patients with chronic lung disease
por: Götschke, Jeremias, et al.
Publicado: (2017)

Clinical, Microbiological, Serological and Radiological Profile of Patients With Mild-Moderate and Severe Allergic Bronchopulmonary Aspergillosis (ABPA)
por: Singh, Amardeep, et al.
Publicado: (2023)

Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma
por: Castro, Mario, et al.
Publicado: (2020)

Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab
por: van Dijk, Yoni E., et al.
Publicado: (2023)

Reply to “Benralizumab as a First-line Treatment for ABPA: Is It Really Indicated?”
por: Matsuura, Hiroaki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_642vj5m3tmibv8ijltn8l22bhq